To The Moon
Home
News
TigerAI
Log In
Sign Up
YaKai
+Follow
Posts · 13
Posts · 13
Following · 0
Following · 0
Followers · 0
Followers · 0
YaKai
YaKai
·
2021-08-23
how far can pfizer go
Pfizer and BioNTech SE shares surged in premarket trading
Pfizer and BioNTech SE shares surged in premarket trading.The F.D.A. is aiming to give full approval
Pfizer and BioNTech SE shares surged in premarket trading
看
2.49K
回复
1
点赞
3
编组 21备份 2
Share
Report
YaKai
YaKai
·
2021-08-17
dont seem that good
Sorry, this post has been deleted
看
2.02K
回复
Comment
点赞
3
编组 21备份 2
Share
Report
YaKai
YaKai
·
2021-08-14
social media advertisement is good money
Sorry, this post has been deleted
看
2.32K
回复
3
点赞
5
编组 21备份 2
Share
Report
YaKai
YaKai
·
2021-08-11
any upsides for apple?
Sorry, this post has been deleted
看
1.94K
回复
Comment
点赞
Like
编组 21备份 2
Share
Report
YaKai
YaKai
·
2021-08-09
same old faang?
Sorry, this post has been deleted
看
2.49K
回复
3
点赞
4
编组 21备份 2
Share
Report
YaKai
YaKai
·
2021-07-08
up and up
Sorry, this post has been deleted
看
2.13K
回复
Comment
点赞
Like
编组 21备份 2
Share
Report
YaKai
YaKai
·
2021-07-08
aapl!
看
2.31K
回复
Comment
点赞
Like
编组 21备份 2
Share
Report
YaKai
YaKai
·
2021-06-26
IWDA trades?
看
1.84K
回复
Comment
点赞
Like
编组 21备份 2
Share
Report
YaKai
YaKai
·
2021-06-26
Would MSFT have a really positive outlook?
Sorry, this post has been deleted
看
2.23K
回复
Comment
点赞
Like
编组 21备份 2
Share
Report
YaKai
YaKai
·
2021-06-26
like please
Sorry, this post has been deleted
看
1.75K
回复
Comment
点赞
3
编组 21备份 2
Share
Report
Load more
Most Discussed
{"i18n":{"language":"en_US"},"isCurrentUser":false,"userPageInfo":{"id":"3574510570116544","uuid":"3574510570116544","gmtCreate":1611416547717,"gmtModify":1611416547717,"name":"YaKai","pinyin":"yakai","introduction":"","introductionEn":null,"signature":"","avatar":"https://static.laohu8.com/default-avatar.jpg","hat":null,"hatId":null,"hatName":null,"vip":1,"status":2,"fanSize":3,"headSize":7,"tweetSize":13,"questionSize":0,"limitLevel":999,"accountStatus":4,"level":{"id":1,"name":"萌萌虎","nameTw":"萌萌虎","represent":"呱呱坠地","factor":"评论帖子3次或发布1条主帖（非转发）","iconColor":"3C9E83","bgColor":"A2F1D9"},"themeCounts":0,"badgeCounts":0,"badges":[],"moderator":false,"superModerator":false,"manageSymbols":null,"badgeLevel":null,"boolIsFan":false,"boolIsHead":false,"favoriteSize":0,"symbols":null,"coverImage":null,"realNameVerified":"success","userBadges":[{"badgeId":"1026c425416b44e0aac28c11a0848493-3","templateUuid":"1026c425416b44e0aac28c11a0848493","name":" Tiger Idol","description":"Join the tiger community for 1500 days","bigImgUrl":"https://static.tigerbbs.com/8b40ae7da5bf081a1c84df14bf9e6367","smallImgUrl":"https://static.tigerbbs.com/f160eceddd7c284a8e1136557615cfad","grayImgUrl":"https://static.tigerbbs.com/11792805c468334a9b31c39f95a41c6a","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2025.03.04","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1001},{"badgeId":"972123088c9646f7b6091ae0662215be-1","templateUuid":"972123088c9646f7b6091ae0662215be","name":"Elite Trader","description":"Total number of securities or futures transactions reached 30","bigImgUrl":"https://static.tigerbbs.com/ab0f87127c854ce3191a752d57b46edc","smallImgUrl":"https://static.tigerbbs.com/c9835ce48b8c8743566d344ac7a7ba8c","grayImgUrl":"https://static.tigerbbs.com/76754b53ce7a90019f132c1d2fbc698f","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2024.10.23","exceedPercentage":"60.50%","individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1100},{"badgeId":"7a9f168ff73447fe856ed6c938b61789-1","templateUuid":"7a9f168ff73447fe856ed6c938b61789","name":"Knowledgeable Investor","description":"Traded more than 10 stocks","bigImgUrl":"https://static.tigerbbs.com/e74cc24115c4fbae6154ec1b1041bf47","smallImgUrl":"https://static.tigerbbs.com/d48265cbfd97c57f9048db29f22227b0","grayImgUrl":"https://static.tigerbbs.com/76c6d6898b073c77e1c537ebe9ac1c57","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2024.08.31","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1102},{"badgeId":"a83d7582f45846ffbccbce770ce65d84-1","templateUuid":"a83d7582f45846ffbccbce770ce65d84","name":"Real Trader","description":"Completed a transaction","bigImgUrl":"https://static.tigerbbs.com/2e08a1cc2087a1de93402c2c290fa65b","smallImgUrl":"https://static.tigerbbs.com/4504a6397ce1137932d56e5f4ce27166","grayImgUrl":"https://static.tigerbbs.com/4b22c79415b4cd6e3d8ebc4a0fa32604","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.21","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1100}],"userBadgeCount":4,"currentWearingBadge":null,"individualDisplayBadges":null,"crmLevel":11,"crmLevelSwitch":0,"location":null,"starInvestorFollowerNum":0,"starInvestorFlag":false,"starInvestorOrderShareNum":0,"subscribeStarInvestorNum":1,"ror":null,"winRationPercentage":null,"showRor":false,"investmentPhilosophy":null,"starInvestorSubscribeFlag":false},"page":1,"watchlist":null,"tweetList":[{"id":835849018,"gmtCreate":1629706613634,"gmtModify":1676530105615,"author":{"id":"3574510570116544","authorId":"3574510570116544","name":"YaKai","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3574510570116544","authorIdStr":"3574510570116544"},"themes":[],"htmlText":"how far can pfizer go","listText":"how far can pfizer go","text":"how far can pfizer go","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":1,"repostSize":0,"link":"https://ttm.financial/post/835849018","repostId":"1104804215","repostType":4,"repost":{"id":"1104804215","kind":"news","weMediaInfo":{"introduction":"Providing stock market headlines, business news, financials and earnings ","home_visible":1,"media_name":"Tiger Newspress","id":"1079075236","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1629706373,"share":"https://ttm.financial/m/news/1104804215?lang=&edition=fundamental","pubTime":"2021-08-23 16:12","market":"us","language":"en","title":"Pfizer and BioNTech SE shares surged in premarket trading","url":"https://stock-news.laohu8.com/highlight/detail?id=1104804215","media":"Tiger Newspress","summary":"Pfizer and BioNTech SE shares surged in premarket trading.The F.D.A. is aiming to give full approval","content":"<p>Pfizer and BioNTech SE shares surged in premarket trading.The F.D.A. is aiming to give full approval to Pfizer’s Covid vaccine on Monday,according to the New York Times.</p>\n<p><img src=\"https://static.tigerbbs.com/7fdc37e9193346a16038693153dd045e\" tg-width=\"362\" tg-height=\"125\" width=\"100%\" height=\"auto\"></p>\n<p>The Food and Drug Administration is pushing to approve Pfizer-BioNTech’s two-dose Covid-19 vaccine on Monday, further expediting an earlier timeline for licensing the shot, according to people familiar with the agency’s planning.</p>\n<p>Regulators were working to finish the process by Friday but were still working through a substantial amount of paperwork and negotiation with the company. The people familiar with the planning, who were not authorized to speak publicly about it, cautioned that the approval might slide beyond Monday if some components of the review need more time.</p>\n<p>An F.D.A. spokeswoman declined to comment.</p>\n<p>The agency had recently set an unofficial deadline for approval of around Labor Day.</p>\n<p>The approval is expected to pave the way for a series of vaccination requirements by public and private organizations who were awaiting final regulatory action before putting in effect mandates. Federal and state health officials are also hoping that an approved vaccine will draw interest from some Americans who have been hesitant to take one that was only authorized for emergency use, a phenomenon suggested by recent polling.</p>\n<p>Some universities and hospitals are expected to mandate inoculation once a vaccine is fully approved. The Pentagon this month said it planned to make Covid vaccinations mandatory for the country’s 1.3 million active-duty troops “no later” than the middle of next month, or sooner if the F.D.A. acts earlier.</p>\n<p>Once it obtains the approval, Pfizer-BioNTech is planning to quickly ask the F.D.A. to approve a third dose as a booster shot. The Biden administration on Wednesday announced that fully vaccinated adults should prepare to get booster shots eight months after they received their second doses, beginning Sept. 20. Pfizer is expected to finish submitting data that it says shows a third shot is safe and effective next week.</p>\n<p>The F.D.A. last week updated its authorizations of Pfizer-BioNTech’s and Moderna’s vaccines to allow third doses for some immunocompromised people, a decision backed by the Centers for Disease Control and Prevention.</p>\n<p>Regulators are still reviewing Moderna’s application for full approval for its coronavirus vaccine, and a decision could come at least several weeks after the one for Pfizer-BioNTech. Moderna is planning to submit its data in support of a booster shot in September.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Pfizer and BioNTech SE shares surged in premarket trading</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nPfizer and BioNTech SE shares surged in premarket trading\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1079075236\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Tiger Newspress </p>\n<p class=\"h-time\">2021-08-23 16:12</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Pfizer and BioNTech SE shares surged in premarket trading.The F.D.A. is aiming to give full approval to Pfizer’s Covid vaccine on Monday,according to the New York Times.</p>\n<p><img src=\"https://static.tigerbbs.com/7fdc37e9193346a16038693153dd045e\" tg-width=\"362\" tg-height=\"125\" width=\"100%\" height=\"auto\"></p>\n<p>The Food and Drug Administration is pushing to approve Pfizer-BioNTech’s two-dose Covid-19 vaccine on Monday, further expediting an earlier timeline for licensing the shot, according to people familiar with the agency’s planning.</p>\n<p>Regulators were working to finish the process by Friday but were still working through a substantial amount of paperwork and negotiation with the company. The people familiar with the planning, who were not authorized to speak publicly about it, cautioned that the approval might slide beyond Monday if some components of the review need more time.</p>\n<p>An F.D.A. spokeswoman declined to comment.</p>\n<p>The agency had recently set an unofficial deadline for approval of around Labor Day.</p>\n<p>The approval is expected to pave the way for a series of vaccination requirements by public and private organizations who were awaiting final regulatory action before putting in effect mandates. Federal and state health officials are also hoping that an approved vaccine will draw interest from some Americans who have been hesitant to take one that was only authorized for emergency use, a phenomenon suggested by recent polling.</p>\n<p>Some universities and hospitals are expected to mandate inoculation once a vaccine is fully approved. The Pentagon this month said it planned to make Covid vaccinations mandatory for the country’s 1.3 million active-duty troops “no later” than the middle of next month, or sooner if the F.D.A. acts earlier.</p>\n<p>Once it obtains the approval, Pfizer-BioNTech is planning to quickly ask the F.D.A. to approve a third dose as a booster shot. The Biden administration on Wednesday announced that fully vaccinated adults should prepare to get booster shots eight months after they received their second doses, beginning Sept. 20. Pfizer is expected to finish submitting data that it says shows a third shot is safe and effective next week.</p>\n<p>The F.D.A. last week updated its authorizations of Pfizer-BioNTech’s and Moderna’s vaccines to allow third doses for some immunocompromised people, a decision backed by the Centers for Disease Control and Prevention.</p>\n<p>Regulators are still reviewing Moderna’s application for full approval for its coronavirus vaccine, and a decision could come at least several weeks after the one for Pfizer-BioNTech. Moderna is planning to submit its data in support of a booster shot in September.</p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BNTX":"BioNTech SE","PFE":"辉瑞"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1104804215","content_text":"Pfizer and BioNTech SE shares surged in premarket trading.The F.D.A. is aiming to give full approval to Pfizer’s Covid vaccine on Monday,according to the New York Times.\n\nThe Food and Drug Administration is pushing to approve Pfizer-BioNTech’s two-dose Covid-19 vaccine on Monday, further expediting an earlier timeline for licensing the shot, according to people familiar with the agency’s planning.\nRegulators were working to finish the process by Friday but were still working through a substantial amount of paperwork and negotiation with the company. The people familiar with the planning, who were not authorized to speak publicly about it, cautioned that the approval might slide beyond Monday if some components of the review need more time.\nAn F.D.A. spokeswoman declined to comment.\nThe agency had recently set an unofficial deadline for approval of around Labor Day.\nThe approval is expected to pave the way for a series of vaccination requirements by public and private organizations who were awaiting final regulatory action before putting in effect mandates. Federal and state health officials are also hoping that an approved vaccine will draw interest from some Americans who have been hesitant to take one that was only authorized for emergency use, a phenomenon suggested by recent polling.\nSome universities and hospitals are expected to mandate inoculation once a vaccine is fully approved. The Pentagon this month said it planned to make Covid vaccinations mandatory for the country’s 1.3 million active-duty troops “no later” than the middle of next month, or sooner if the F.D.A. acts earlier.\nOnce it obtains the approval, Pfizer-BioNTech is planning to quickly ask the F.D.A. to approve a third dose as a booster shot. The Biden administration on Wednesday announced that fully vaccinated adults should prepare to get booster shots eight months after they received their second doses, beginning Sept. 20. Pfizer is expected to finish submitting data that it says shows a third shot is safe and effective next week.\nThe F.D.A. last week updated its authorizations of Pfizer-BioNTech’s and Moderna’s vaccines to allow third doses for some immunocompromised people, a decision backed by the Centers for Disease Control and Prevention.\nRegulators are still reviewing Moderna’s application for full approval for its coronavirus vaccine, and a decision could come at least several weeks after the one for Pfizer-BioNTech. Moderna is planning to submit its data in support of a booster shot in September.","news_type":1,"symbols_score_info":{"PFE":0.9,"BNTX":0.9}},"isVote":1,"tweetType":1,"viewCount":2485,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":839865632,"gmtCreate":1629150173826,"gmtModify":1676529943651,"author":{"id":"3574510570116544","authorId":"3574510570116544","name":"YaKai","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3574510570116544","authorIdStr":"3574510570116544"},"themes":[],"htmlText":"dont seem that good","listText":"dont seem that good","text":"dont seem that good","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/839865632","repostId":"2159193222","repostType":4,"isVote":1,"tweetType":1,"viewCount":2015,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":897942395,"gmtCreate":1628870865517,"gmtModify":1676529882785,"author":{"id":"3574510570116544","authorId":"3574510570116544","name":"YaKai","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3574510570116544","authorIdStr":"3574510570116544"},"themes":[],"htmlText":"social media advertisement is good money","listText":"social media advertisement is good money","text":"social media advertisement is good money","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":5,"commentSize":3,"repostSize":0,"link":"https://ttm.financial/post/897942395","repostId":"2159657218","repostType":4,"isVote":1,"tweetType":1,"viewCount":2321,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":892076880,"gmtCreate":1628621007140,"gmtModify":1676529799280,"author":{"id":"3574510570116544","authorId":"3574510570116544","name":"YaKai","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3574510570116544","authorIdStr":"3574510570116544"},"themes":[],"htmlText":"any upsides for apple?","listText":"any upsides for apple?","text":"any upsides for apple?","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/892076880","repostId":"1160585513","repostType":4,"isVote":1,"tweetType":1,"viewCount":1938,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":898257775,"gmtCreate":1628504422697,"gmtModify":1703507197654,"author":{"id":"3574510570116544","authorId":"3574510570116544","name":"YaKai","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3574510570116544","authorIdStr":"3574510570116544"},"themes":[],"htmlText":"same old faang?","listText":"same old faang?","text":"same old faang?","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":3,"repostSize":0,"link":"https://ttm.financial/post/898257775","repostId":"2157492988","repostType":4,"isVote":1,"tweetType":1,"viewCount":2488,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":149008317,"gmtCreate":1625680655939,"gmtModify":1703746352149,"author":{"id":"3574510570116544","authorId":"3574510570116544","name":"YaKai","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3574510570116544","authorIdStr":"3574510570116544"},"themes":[],"htmlText":"up and up","listText":"up and up","text":"up and up","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/149008317","repostId":"2149315125","repostType":2,"isVote":1,"tweetType":1,"viewCount":2132,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":149001293,"gmtCreate":1625680594612,"gmtModify":1703746350991,"author":{"id":"3574510570116544","authorId":"3574510570116544","name":"YaKai","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3574510570116544","authorIdStr":"3574510570116544"},"themes":[],"htmlText":"aapl!","listText":"aapl!","text":"aapl!","images":[{"img":"https://static.tigerbbs.com/8987e34c89f0f3f391aab08ad49e4b6a","width":"1125","height":"2183"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/149001293","isVote":1,"tweetType":1,"viewCount":2311,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"EN","totalScore":0},{"id":125479721,"gmtCreate":1624689270463,"gmtModify":1703843724737,"author":{"id":"3574510570116544","authorId":"3574510570116544","name":"YaKai","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3574510570116544","authorIdStr":"3574510570116544"},"themes":[],"htmlText":"IWDA trades?","listText":"IWDA trades?","text":"IWDA trades?","images":[{"img":"https://static.tigerbbs.com/3668b6162134f4a0fb6c92c55fff7885","width":"1125","height":"1814"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/125479721","isVote":1,"tweetType":1,"viewCount":1835,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"EN","totalScore":0},{"id":125479904,"gmtCreate":1624689225008,"gmtModify":1703843723281,"author":{"id":"3574510570116544","authorId":"3574510570116544","name":"YaKai","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3574510570116544","authorIdStr":"3574510570116544"},"themes":[],"htmlText":"Would MSFT have a really positive outlook?","listText":"Would MSFT have a really positive outlook?","text":"Would MSFT have a really positive outlook?","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/125479904","repostId":"2146036830","repostType":4,"isVote":1,"tweetType":1,"viewCount":2233,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":125447595,"gmtCreate":1624689127617,"gmtModify":1703843721016,"author":{"id":"3574510570116544","authorId":"3574510570116544","name":"YaKai","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3574510570116544","authorIdStr":"3574510570116544"},"themes":[],"htmlText":"like please","listText":"like please","text":"like please","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/125447595","repostId":"1108941456","repostType":4,"isVote":1,"tweetType":1,"viewCount":1746,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0}],"defaultTab":"posts","isTTM":true}